Since our IPM is based on tumor microenvironment-related genes, although its establishment is related to EGFR mutation, ALK translocation, ROS1 translocation, and BRAF mutation, it is applicable to all patients with or without these mutations in stage I-II LUAD. The gene discussed is ALK; the disease is neoplasm.